GI Partners Acquires Majority Stake in Clinical Ink

August 4, 2020

GI Partners will acquire a majority interest in Clinical Ink, a global clinical trial technology company headquartered in Horsham, Pennsylvania. The private investment firm will partner with Clinical Ink's management to accelerate product innovation, expand capabilities internationally, and pursue growth; existing investor NovaQuest will remain a minority shareholder. The transaction was expected to close in Q3 2020, subject to customary closing conditions.

Buyers
GI Partners
Targets
Clinical Ink
Industry
Cloud & SaaS
Location
Pennsylvania, United States
Transaction Type
Buyout

Explore More

Related Acquisitions

Track M&A activity that matters to you

Get real-time deal alerts, build buyer lists with AI, and access our full acquisition database. Start your free trial today.